Premium
Weighted estimators of the complier average causal effect on restricted mean survival time with observed instrument–outcome confounders
Author(s) -
Dharmarajan Sai H.,
Li Yun,
Lehmann Douglas,
Schaubel Douglas E.
Publication year - 2021
Publication title -
biometrical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 63
eISSN - 1521-4036
pISSN - 0323-3847
DOI - 10.1002/bimj.201900284
Subject(s) - estimator , covariate , censoring (clinical trials) , observational study , propensity score matching , causal inference , confounding , statistics , instrumental variable , econometrics , outcome (game theory) , average treatment effect , population , inverse probability , survival analysis , matching (statistics) , mathematics , medicine , bayesian probability , environmental health , mathematical economics , posterior probability
A major concern in any observational study is unmeasured confounding of the relationship between a treatment and outcome of interest. Instrumental variable (IV) analysis methods are able to control for unmeasured confounding. However, IV analysis methods developed for censored time‐to‐event data tend to rely on assumptions that may not be reasonable in many practical applications, making them unsuitable for use in observational studies. In this report, we develop weighted estimators of the complier average causal effect (CACE) on the restricted mean survival time in the overall population as well as in an evenly matchable population (CACE‐m). Our method is able to accommodate instrument–outcome confounding and adjust for covariate‐dependent censoring, making it particularly suited for causal inference from observational studies. We establish the asymptotic properties and derive easily implementable asymptotic variance estimators for the proposed estimators. Through simulation studies, we show that the proposed estimators tend to be more efficient than instrument propensity score matching‐based estimators or IPIW estimators. We apply our method to compare dialytic modality‐specific survival for end stage renal disease patients using data from the U.S. Renal Data System.